QualityStocks News - International Stem Cell Corp. (ISCO) Firmly Rooted in Biotech Space with Innovative Technology, Unique Business Model

QualityStocks would like to highlight International Stem Cell Corporation (OTCBB: ISCO), focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs).

In the company’s news,

International Stem Cell Corp. is focused on the application of its research and development to the treatment of human degenerative diseases.

The company’s human parthenogenetic stem cells (hpSCs), derived from unfertilized human eggs, have the best characteristics of each of the most commonly used and described classes of stem cells – induced pluripotent stem cells, embryonic stem cells, and adult stem cells – thereby creating a class of cells that meet all important criteria when it comes to therapeutic application.

hsPCs’ are immune matching, which means that millions of patients could receive tissue and cell transplants without tissue rejection problems or the need to take immune-suppressing drugs; pluripotent, meaning they can change or “differentiate” into more specialized cells such as skin, liver or blood cells; demonstrate strong proliferation in culture, which refers to the growth of the cell populations in the research and/or application environment; and are considered superior in their use in genetic disease.

Leveraging these capabilities and characteristics, International Stem Cell aims to use its hsPCs to treat diseases of the brain (Parkinson’s diseases), liver (treatment of liver damage) and eye (cornea tissue implants). In support of these goals, the company is also building its stem cell bank (UniStemCell) of parthenogenetic stem cell lines for research and commercial use.

International Stem Cell’s subsidiary business units, Lifeline Cell Technology (LCT) and Lifeline Skin Care (LSC), further support the company and create a business model unique to the biotechnology industry, creating revenue flow from the sale of products develop from scientific discoveries made by International Stem Cell. This self-sustaining model not only allows for the allocation of revenues to further support scientific research and development, but also provides practical, short-term applications of the company’s core technologies.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net  

To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage

To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks

Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net   

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.